$0.98
-0.08 (-7.56%)
Open$1.02
Previous Close$1.06
Day High$1.02
Day Low$0.91
52W High$20.76
52W Low$0.90
Volume—
Avg Volume48.0K
Market Cap2.38M
P/E Ratio—
EPS$-934.89
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+4,466.2% upside
Current
$0.98
$0.98
Target
$44.53
$44.53
$37.12
$44.53 avg
$63.68
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.28M | 1.20M | 1.36M |
| Net Income | 141.5K | 105.1K | 144.5K |
| Profit Margin | 11.1% | 8.8% | 10.6% |
| EBITDA | 291.4K | 241.4K | 275.9K |
| Free Cash Flow | 83.4K | 101.2K | 72.7K |
| Rev Growth | +11.3% | +13.4% | -9.5% |
| Debt/Equity | 0.31 | 0.28 | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.55 | -0.16% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $456.60 | -1.24% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $169.42 | +1.10% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $531.97 | -1.08% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $951.08 | -0.14% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $159.73 | -3.22% | 7.7 | 20.98B |